4
Views
4
CrossRef citations to date
0
Altmetric
Articles

Effects of High Dose Medroxyprogesterone Acetate Treatment on Antithrombin III and other Plasma Proteins In Males With Renal Cell or Prostatic Carcinoma

, &
Pages 11-14 | Published online: 31 Mar 2016

Literature cited

  • Aronsen KF, Ekelund G, Kindmark CO, Laurell CB. Sequential changes of plasma proteins after surgical trauma. Scand J Clin Lab Invest 1972; 29 (Suppl 124): 127–136.
  • Blossey HC, Wander HE, Koebberling J, Nagel GA. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 1984; 54: 1208–1215.
  • Bono VA. Steroid hormones and hormonal treatment in renal cell carcinoma. In: deKernion JB, Pavone-Macaluso M, eds. Tumors of the kidney. Baltimore: Williams & Wilkins, 1986: 205–227.
  • Bonsignori M, Rossi G, Sturba F and associates. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. Chemioterapia 1986; 5: 134–139.
  • Buller HR, Boon TA, Henny CP, Dabhoiwala NF, Ten Cate JW. Estrogen-induced deficiency and decrease in antithrombin III activity in patients with prostatic cancer. J Urol 1982; 128:72–74.
  • Cejka J. Enzyme immunoassay for Factor VIII-related antigen. Clin Chem 1982; 28:1356–1358.
  • Doobs RM, Barber JA, Weigel JW, Bergin JE. Clotting predisposition in carcinoma of the prostate. J Urol 1980; 123:706–709.
  • Ganrot PO. Variation of the concentrations of some plasma proteins in normal adults, in pregnant women and in newborns. Scand J Clin Lab Invest 1972; 29 (Suppl 124): 83–88. 9.
  • Johansson J-E, Lingard G. High-dose medroxyprogesterone in the treatment of advanced prostatic carcinoma. Eur Urol 1985; 11:9–10.
  • Kauffman RH, Veltkamp JJ, Van Tilburg NH, Van Es LA. Acquired antithrobin III deficiency and trombosis in the nephrotic syndrome. Am J Med 1978; 65:607–613.
  • Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15:45–52.
  • Laurell CB, Kullander S, Thorell J. .Plasma proteins after continuous, oral use of a progestogen-chloroma-dionone acetate-as a contraceptive. Scand J Clin Lab Invest 1969; 24:387–389.
  • Mahlke M, Grill H-J, Knapstein P, Wiegand U, Pollow K. Oral high-dose medroxyprogesterone acetate (MPA) treatment: cortisol/MPA serum profiles in relation to breast cancer regression. Oncology 1985; 42: 144–149.
  • Nilsson T. Aspects of Cl-inhibitor biochemistry and pathophysiology. Clin Rheumatol 1987; 6:332–339.
  • Pavone-Macaluso M, DcVoogt HJ, Viggiano G, Bara-solo E, Lardennois B, DePauw M, Sylvester R. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: Final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer: Urological group. J Urol 1986; 136:624–631.
  • Rosso R, Boccardo F, Canobbio L, Queirolo MA, Zar-cone D, Brema F. Effects of high-dose medroxyprogesterone acetate on blood-clotting factors and platelet function. In: Cavalli F, McGuire WL, Panutti F, Pellegrini A, Robustelli Delia Cuna G, eds. Proceedings of the international symposium on medroxyprogesterone acetate. Amsterdam: Excerpta Medica, 1982: 151–157.
  • Tomic R, Ljungberg B, Damber J-E. Hormonal effects of high dose medroxyprogesterone acetate treatment in males with renal or prostatic adenocarcinoma. Scand J Urol Nephrol 1988 ; 22:15–18.
  • VanVeelen H, Willemse PHB, Slejfer DT, Van der Ploeg E, SluiterWJ, Doorenbos H. Mechanism of adrenal suppression by high-dose medroxyprogesterone acetate in breast cancer patients. Cancer Chemother Pharmacol 1985; 15: 167–170.
  • DeVoogt HJ, Smith PH, Pavone-Macaluso M, DePauw M, Sucio S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine used for the treatment of advanced prostatic cancer: Results from European organisation for research on treatment of cancer trials 30761 and 30762. J Urol 1986; 135:303–307.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.